Back to today’s briefing

Story perspectives

New Drug Abelacimab Reduces Bleeding Risk in Seniors

3/30/2025

24 2

Summary

Story summary

At the American College of Cardiology Annual Scientific Session, Anthos Therapeutics unveiled groundbreaking results from the AZALEA-TIMI 71 study. The innovative Factor XI inhibitor, abelacimab, demonstrated a remarkable reduction in bleeding risk compared to rivaroxaban, particularly benefiting patients aged 75 and older. This promising finding positions abelacimab as a safer option for vulnerable populations.

1 of 1

Story summary

At the American College of Cardiology Annual Scientific Session, Anthos Therapeutics unveiled groundbreaking results from the AZALEA-TIMI 71 study. The innovative Factor XI inhibitor, abelacimab, demonstrated a remarkable reduction in bleeding risk compared to rivaroxaban, particularly benefiting patients aged 75 and older. This promising finding positions abelacimab as a safer option for vulnerable populations.